Brent Boucher - AngioDynamics President
| ANGO Stock | USD 6.31 0.06 0.94% |
President
Mr. Brent J. Boucher is Senior Vice President and General Manager, OncologySurgery of the Company. Prior to joining AngioDynamics in November 2017, Mr. Boucher served as Executive in Residence for PDI Infection Prevention business. Prior to that, he spent 20 years at Covidien where he served as General Manager for several global businesses, including Lung Solutions, Surgical Solutions and Respiratory Care. Mr. Boucher is a graduate of North Dakota State University. since 2017.
| Age | 50 |
| Tenure | 7 years |
| Address | 14 Plaza Drive, Latham, NY, United States, 12110 |
| Phone | 518 795 1400 |
| Web | https://www.angiodynamics.com |
AngioDynamics Management Efficiency
The company has return on total asset (ROA) of (0.0481) % which means that it has lost $0.0481 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6242) %, meaning that it created substantial loss on money invested by shareholders. AngioDynamics' management efficiency ratios could be used to measure how well AngioDynamics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 16th of April 2024, Return On Tangible Assets is likely to grow to -0.22. In addition to that, Return On Capital Employed is likely to grow to -0.05. At this time, AngioDynamics' Other Assets are very stable compared to the past year. As of the 16th of April 2024, Other Current Assets is likely to grow to about 4.5 M, while Total Assets are likely to drop about 533.4 M.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| R Ussery | National HealthCare | 60 | |
| John Saich | Select Medical Holdings | 55 | |
| Leroy McIntosh | National HealthCare | 63 | |
| B Flatt | National HealthCare | 57 | |
| Peter Mantegazza | Encompass Health Corp | N/A | |
| Brian Wayment | Pennant Group | N/A | |
| Gerald Coggin | National HealthCare | 62 | |
| Michael Tarvin | Select Medical Holdings | 63 | |
| Thomas Mullin | Select Medical Holdings | 40 | |
| Robert Breighner | Select Medical Holdings | 55 | |
| John Lines | National HealthCare | 57 | |
| Douglas Coltharp | Encompass Health Corp | 62 | |
| Jeffrey Smith | National HealthCare | 61 | |
| Julia Powell | National HealthCare | 68 | |
| Martin Jackson | Select Medical Holdings | 69 | |
| Patrick Darby | Encompass Health Corp | 56 | |
| Josh McCreary | National HealthCare | 51 | |
| Scott Romberger | Select Medical Holdings | 63 | |
| Spencer Burton | The Ensign Group | 45 | |
| Brian Kidd | National HealthCare | 49 | |
| Michael Ussery | National HealthCare | 65 | |
Management Performance
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.0481 |
AngioDynamics Leadership Team
Elected by the shareholders, the AngioDynamics' board of directors comprises two types of representatives: AngioDynamics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AngioDynamics. The board's role is to monitor AngioDynamics' management team and ensure that shareholders' interests are well served. AngioDynamics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AngioDynamics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ben Davis, Senior Vice President Business Development | ||
| Michael Trimarchi, Interim CFO, VP and Global Controller | ||
| Jeffrey Gold, Independent Director | ||
| Chad Campbell, Senior Vice President and General Manager, Vascular Access | ||
| Steven Laporte, Independent Director | ||
| David Helsel, Senior Vice President - Global Operations | ||
| Jan Reed, Director | ||
| Dennis Meteny, Independent Director | ||
| Eileen Auen, Director | ||
| Wesley Johnson, Independent Director | ||
| Mark Stephens, Sr. VP of Admin. | ||
| Stephen Trowbridge, Sr. VP, General Counsel and Assistant Secretary | ||
| Heather DanielsCariveau, Senior Vice President-Human Resources | ||
| Saleem Cheeks, Vice Communications | ||
| John Soto, Chief Commercial Officer and Executive VP | ||
| Benjamin Davis, Senior Vice President Business Development | ||
| Barbara Kucharczyk, Senior Vice President-Global Operations | ||
| Robert Simpson, Senior Vice President and General Manager, Peripheral Vascular | ||
| Kevin Gould, Independent Director | ||
| Michael Greiner, CFO, Executive Vice President | ||
| Laura Piccinini, Senior International | ||
| Warren Nighan, Senior Vice President-Senior Vice President Quality & Regulatory Affairs | ||
| Sriram Venkataraman, Independent Director | ||
| Brent Boucher, Senior Vice President and General Manager, Oncology/Surgery | ||
| Joseph DeVivo, CEO and President and Director | ||
| Scott Centea, Senior Therapies | ||
| James Clemmer, President CEO, Director | ||
| Caitlin Stefanik, IR Contact Officer | ||
| Richard Rosenzweig, Gen VP | ||
| Christopher Dailey, IR Contact Officer | ||
| Marna BronfenMoore, Senior Resources | ||
| Kim Seabury, Senior Vice President Information Technology | ||
| Juan Serna, Senior Affairs | ||
| Karen Licitra, Independent Director | ||
| Gary Barrett, Senior Vice President Quality and Regulatory Affairs | ||
| David Burgstahler, Independent Director | ||
| Howard Donnelly, Independent Chairman of the Board |
AngioDynamics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AngioDynamics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.0481 | ||||
| Profit Margin | (0.59) % | ||||
| Operating Margin | (0.19) % | ||||
| Current Valuation | 180.66 M | ||||
| Shares Outstanding | 40.05 M | ||||
| Shares Owned By Insiders | 4.99 % | ||||
| Shares Owned By Institutions | 91.31 % | ||||
| Number Of Shares Shorted | 2.25 M | ||||
| Price To Earning | 7.90 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards AngioDynamics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, AngioDynamics' short interest history, or implied volatility extrapolated from AngioDynamics options trading.
Pair Trading with AngioDynamics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AngioDynamics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AngioDynamics will appreciate offsetting losses from the drop in the long position's value.Moving against AngioDynamics Stock
| 0.66 | NXGL | Nexgel Inc | PairCorr |
| 0.49 | ENSG | Ensign Group Financial Report 24th of April 2024 | PairCorr |
| 0.46 | COO | Cooper Companies Financial Report 6th of June 2024 | PairCorr |
| 0.42 | CVS | CVS Health Corp Financial Report 1st of May 2024 | PairCorr |
| 0.41 | POAI | Predictive Oncology | PairCorr |
The ability to find closely correlated positions to AngioDynamics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AngioDynamics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AngioDynamics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AngioDynamics to buy it.
The correlation of AngioDynamics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AngioDynamics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AngioDynamics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AngioDynamics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AngioDynamics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in AngioDynamics Stock, please use our How to Invest in AngioDynamics guide.Note that the AngioDynamics information on this page should be used as a complementary analysis to other AngioDynamics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Complementary Tools for AngioDynamics Stock analysis
When running AngioDynamics' price analysis, check to measure AngioDynamics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AngioDynamics is operating at the current time. Most of AngioDynamics' value examination focuses on studying past and present price action to predict the probability of AngioDynamics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AngioDynamics' price. Additionally, you may evaluate how the addition of AngioDynamics to your portfolios can decrease your overall portfolio volatility.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |
Is AngioDynamics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AngioDynamics. If investors know AngioDynamics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AngioDynamics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.80) | Revenue Per Share 8.105 | Quarterly Revenue Growth (0.07) | Return On Assets (0.05) | Return On Equity (0.62) |
The market value of AngioDynamics is measured differently than its book value, which is the value of AngioDynamics that is recorded on the company's balance sheet. Investors also form their own opinion of AngioDynamics' value that differs from its market value or its book value, called intrinsic value, which is AngioDynamics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AngioDynamics' market value can be influenced by many factors that don't directly affect AngioDynamics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AngioDynamics' value and its price as these two are different measures arrived at by different means. Investors typically determine if AngioDynamics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AngioDynamics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.